Videos / Recombinant respiratory syncytial virus pre-fusion F protein vaccine

Product Explainer

Recombinant respiratory syncytial virus pre-fusion F protein vaccine

Description

In this Product Explainer, Infectious Disease Physician and Microbiologist Prof Paul Griffin explains the role of a recombinant respiratory syncytial virus pre-fusion F protein vaccine for prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).

Additional resources

NCIRS FAQ: Respiratory syncytial virus (RSV) FAQs | NCIRS.
NCIRS Fact Sheet – state funding of Nirsevimab, eligibility criteria by state: State and territory nirsevimab program summary 2025.pdf

NEXT LIVE Webcast

Days

Hours

Minutes

Seconds

A/Prof Samantha Hocking

Tirzepatide Compared to Semaglutide for Treatment of Obesity – Latest Evidence

A/Prof Gino Pecoraro OAM

Genitourinary Syndrome of Menopause – Mythbusting for GPs

Prof Sonia Grover

Dysmenorrhoea in Teens

Prof Paul Griffin

Winter Virus Preparations

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

27 May 2025

expert

Prof Paul Griffin

Infectious Diseases Physician and Clinical Microbiologist; Director of Infectious Diseases, Mater Hospital; Lecturer, University of Queensland

Product Explainer

Recombinant respiratory syncytial virus pre-fusion F protein vaccine